| (Values in U.S. Thousands) | Jun, 2020 | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 |
| Sales | 50,000 | 0 | 0 | 0 | 30,000 |
| Sales Growth | unch | unch | unch | -100.00% | +481.40% |
| Net Income | 10,810 | -32,500 | -24,920 | -22,300 | 7,120 |
| Net Income Growth | +133.26% | -30.42% | -11.75% | -413.20% | +152.01% |
Principia Biopharma Inc (PRNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco, United States.
Fiscal Year End Date: 12/31